KCM Investment Advisors LLC lessened its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 1.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,688 shares of the medical research company’s stock after selling 23 shares during the quarter. KCM Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $295,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Proficio Capital Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 71.5% in the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after purchasing an additional 253 shares during the period. Cribstone Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 8.7% in the 2nd quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 50 shares during the period. Shine Investment Advisory Services Inc. purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $113,000. Chicago Partners Investment Group LLC purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $108,000. Finally, CWM LLC lifted its stake in shares of Thermo Fisher Scientific by 17.0% in the 2nd quarter. CWM LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 103 shares during the period. Institutional investors own 83.32% of the company’s stock.

TMO has been the subject of a number of research analyst reports. Bank of America Corporation restated a “buy” rating and issued a $210.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. Cleveland Research upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Citigroup Inc. restated a “buy” rating and issued a $201.00 target price (up previously from $182.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 10th. BidaskClub cut Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 27th. Finally, Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $199.00 target price for the company in a research note on Tuesday, July 11th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $203.64.

Thermo Fisher Scientific Inc (TMO) opened at 193.86 on Friday. The stock has a market cap of $75.63 billion, a PE ratio of 33.77 and a beta of 1.05. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $194.43. The firm’s 50-day moving average price is $190.66 and its 200-day moving average price is $176.57.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, topping analysts’ consensus estimates of $2.27 by $0.03. The company had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. Thermo Fisher Scientific’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.03 earnings per share. Equities analysts predict that Thermo Fisher Scientific Inc will post $9.35 earnings per share for the current fiscal year.

In other news, VP Seth H. Hoogasian sold 4,140 shares of the stock in a transaction on Monday, August 28th. The stock was sold at an average price of $177.80, for a total transaction of $736,092.00. Following the completion of the sale, the vice president now owns 25,518 shares in the company, valued at approximately $4,537,100.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Gregory J. Herrema sold 30,000 shares of the stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $176.02, for a total value of $5,280,600.00. Following the sale, the senior vice president now owns 67,016 shares of the company’s stock, valued at approximately $11,796,156.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,738 shares of company stock valued at $9,302,112. 0.49% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.watchlistnews.com/thermo-fisher-scientific-inc-tmo-shares-sold-by-kcm-investment-advisors-llc/1647061.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.